跳至主要内容
临床试验/EUCTR2012-002639-27-IT
EUCTR2012-002639-27-IT进行中(未招募)1 期

A phase II, multicentre study to evaluate the long-term safety and efficacyof MT-1303 in subjects with relapsing-remitting multiple sclerosis whohave completed the MT-1303-E04 study

MITSUBISHI TANABE PHARMA CORPORATIO0 个研究点目标入组 367 人开始时间: 2013年4月11日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
367

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Completion of the 24-week Treatment Period in MT-1303-E04 as per
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 400
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range 0

排除标准

  • 1. Permanent discontinuation of study medication prior to the End of
  • Treatment (EOT) Visit in MT-1303-E04
  • 2. Newly diagnosed diabetes mellitus during MT-1303-E04

研究者

发起方
MITSUBISHI TANABE PHARMA CORPORATIO

相似试验